Synapse - Works

Results (5612)

Rapid non-uniform adaptation to conformation-specific KRAS G12C inhibition

Meeting Abstract

Xue, J.; Zhao, Y.; Aronowitz, J.; Mai, T. T.; Vides, A.; Qeriqi, B.; Kim, D.; Li, C.; de Stanchina, E.; Mazutis, L.; more...
Molecular Cancer Therapeutics (2019)

Fulltext@MSK | Save

Clinical proof of concept for MCLA-128, a bispecific HER2/3 antibody therapy, in NRG1 fusion-positive cancers

Meeting Abstract

Schram, A. M.; O'Reilly, E. M.; Somwar, R.; Benayed, R.; Shameem, S.; Chauhan, T.; Torrisi, J.; Ford, J.; Maussang, D.; Wasserman, E.; more...
Molecular Cancer Therapeutics (2019)

Fulltext@MSK | Save

A phase Ia/Ib, dose-escalation/expansion study of BI 907828, an MDM2-p53 antagonist, in combination with BI 754091, an anti-PD-1 antibody, and BI 754111, an anti-LAG-3 antibody, in patients with advanced solid tumors

Meeting Abstract

Tolcher, A.; Hafez, N.; Yamamoto, N.; Park, J.; Grempler, R.; Lucarelli, A.; Vallaster, M. P.; Wang, B. S.; Hyman, D.
Molecular Cancer Therapeutics (2019)

Fulltext@MSK | Save

Lower cellular activation of cMET signaling network is associated with reduced recurrence risk in stage II colorectal cancer

Meeting Abstract

McDonough, E.; Sood, A.; Ginty, F.; Cho, S.; Graf, J.; Prehn, J.; Dunne, P.; Lindner, A.; Salvucci, M.; Longley, D.; more...
Molecular Cancer Therapeutics (2019)

Fulltext@MSK | Save

Updated results of phase 1 study of ripretinib (DCC-2618), a broad-spectrum KIT and PDGFRA inhibitor, in patients with gastrointestinal stromal tumor (GIST) by line of therapy (NCT02571036)

Meeting Abstract

Chi, P.; Janku, F.; Heinrich, M.; Ganjoo, K.; Gelderblom, H.; Gordon, M.; Jones, R.; Razak, A.; Trent, J.; von Mehren, M.; more...
Molecular Cancer Therapeutics (2019)

Fulltext@MSK | Save

Preliminary results from a phase 2 trial of tipifarnib in squamous cell carcinomas (SCCs) with HRAS mutations

Meeting Abstract

Ho, A.; Brana, I.; Haddad, R.; Bauman, J.; Bible, K.; Faugeras, L.; Oosting, S.; Wong, D. J.; Ahn, M. J.; Boni, V.; more...
Molecular Cancer Therapeutics (2019)

Fulltext@MSK | Save

A phase 1 trial of AG-270 in patients with advanced solid tumors or lymphoma with homozygous MTAP deletion

Meeting Abstract

Heist, R. S.; Gounder, M. M.; Postel-Vinay, S.; Wilson, F.; Garralda, E.; Do, K.; Shapiro, G. I.; Martin-Romano, P.; Wulf, G.; Cooper, M.; more...
Molecular Cancer Therapeutics (2019)

Fulltext@MSK | Save

NP-G2-044, a novel fascin inhibitor, blocks tumor metastasis and increases antitumor immune response

Meeting Abstract

Chung, V.; Tsai, F.; Jhaveri, K.; Wang, Y.; Von Hoff, D. D.; Garmey, E. G.; Zhang, J. J.; Huang, X. Y.
Molecular Cancer Therapeutics (2019)

Fulltext@MSK | Save

T cell receptor gene therapy for a public neoantigen derived from mutated PIK3CA, a dominant driver oncogene in breast and endometrial cancers

Meeting Abstract

Chandran, S.; Ma, J.; Klatt, M. G.; Dundar, F.; Zumbo, P.; Femia, M. R.; Betel, D.; Scheinberg, D. A.; Baker, B. M.; Klebanoff, C. A.
Molecular Cancer Therapeutics (2019)

Fulltext@MSK | Save

Clostridium difficile infection following outpatient cancer surgery

Journal Article

Cohen, B.; Levine, M.; Kamboj, M.
Infection Control and Hospital Epidemiology (2019)

Fulltext@MSK | Save